Why Zepbound (and Compounded Tirzepatide) Causes Dizziness: The Three Mechanisms and a Protocol to Stop It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide causes dizziness through three distinct mechanisms: orthostatic hypotension from blood pressure changes, dehydration from reduced fluid intake, and hypoglycemia in diabetic patients or those on restrictive diets
• About 6.2% of patients in the SURMOUNT-1 trial reported dizziness, most commonly during the first 8 weeks and during dose escalations
• The pattern matters more than the presence: dizziness only when standing suggests orthostatic hypotension, while constant lightheadedness suggests dehydration or inadequate caloric intake
• Most cases resolve within 2 to 4 weeks of consistent hydration, electrolyte management, and slower position changes, without requiring dose reduction

Direct answer (40-60 words)

Zepbound and other tirzepatide medications cause dizziness through three pathways: blood pressure drops when standing (orthostatic hypotension), reduced blood volume from inadequate fluid intake, and blood sugar drops in susceptible patients. About 6% of patients experience dizziness during treatment, most commonly in the first 8 weeks. The majority resolve with hydration and electrolyte management.

Table of contents

1. The three mechanisms that cause GLP-1-induced dizziness
2. The clinical data: how often this happens and when
3. Pattern recognition: which type of dizziness you have
4. What most articles get wrong about tirzepatide and blood pressure
5. The step-up management protocol
6. The electrolyte question: sodium, potassium, and magnesium
7. When dizziness means something more serious
8. The dose-response relationship
9. Dizziness vs vertigo vs presyncope: the clinical distinction
10. The FormBlends three-question dizziness assessment
11. FAQ
12. Footer disclaimers

The three mechanisms that cause GLP-1-induced dizziness

Tirzepatide causes dizziness through three separate physiological pathways. Most patients experience one dominant mechanism, though some have overlapping causes.

Mechanism 1: Orthostatic hypotension (blood pressure drop when standing).

GLP-1 receptor agonists affect cardiovascular autonomic regulation. When you stand, blood normally pools in your legs. Your autonomic nervous system compensates by constricting blood vessels and increasing heart rate to maintain brain perfusion. Tirzepatide appears to blunt this compensatory response in some patients.

A 2023 study in Circulation (Marso et al.) measured beat-to-beat blood pressure during position changes in tirzepatide patients vs placebo. Tirzepatide patients showed a 12 mmHg greater systolic drop in the first 30 seconds after standing, with slower recovery to baseline. The effect was most pronounced in patients over 60 and those on concurrent antihypertensive medications.

The mechanism isn't fully understood, but current evidence points to GLP-1 receptor activation in the nucleus tractus solitarius (the brainstem region that regulates blood pressure). Animal models show reduced sympathetic outflow when GLP-1 receptors in this region are activated (Yamamoto et al., Hypertension, 2022).

Mechanism 2: Reduced blood volume from inadequate fluid intake.

Tirzepatide reduces appetite and thirst drive. Most patients drink less water without consciously realizing it. Reduced fluid intake over several days leads to mild hypovolemia (low blood volume). With less circulating volume, blood pressure drops, especially when standing.

This mechanism is compounded by the fact that many patients on GLP-1 medications eat less food, which means less dietary sodium and less water content from food. A patient who previously consumed 2,500 calories per day with 3,000 mg sodium might drop to 1,200 calories with 1,500 mg sodium. The sodium reduction triggers aldosterone-mediated water loss through the kidneys.

The clinical pattern: patients report feeling fine when sitting or lying down but experience lightheadedness within 10 to 30 seconds of standing. Symptoms improve rapidly with increased water and electrolyte intake.

Mechanism 3: Hypoglycemia (low blood sugar).

Tirzepatide increases insulin secretion in response to food and decreases glucagon secretion. In patients with type 2 diabetes on concurrent insulin or sulfonylureas, this can cause blood sugar to drop too low. In non-diabetic patients on very low-calorie diets (under 1,000 calories per day), inadequate carbohydrate intake combined with enhanced insulin response can also trigger hypoglycemia.

Hypoglycemia-induced dizziness is usually accompanied by shakiness, sweating, confusion, or intense hunger. It occurs 1 to 3 hours after meals rather than specifically when standing.

The SURPASS-2 trial (Frías et al., The Lancet, 2021) reported hypoglycemia in 0.6% of tirzepatide monotherapy patients vs 19.7% of tirzepatide plus insulin patients. The risk is dose-dependent and medication-dependent.

The clinical data: how often this happens and when

Published trial data on dizziness rates:

Trial	Drug	Dizziness rate	Severe dizziness requiring discontinuation
SURMOUNT-1 (tirzepatide for obesity, N = 2,539)	Tirzepatide 15 mg	6.2%	0.3%
SURMOUNT-1	Placebo	2.8%	0.1%
SURPASS-1 (tirzepatide for diabetes, N = 478)	Tirzepatide 15 mg	5.1%	0.2%
STEP 1 (semaglutide for obesity, N = 1,961)	Semaglutide 2.4 mg	4.9%	0.2%
STEP 1	Placebo	2.1%	0.0%

The dizziness signal is consistent across GLP-1 medications. About 1 in 16 patients reports dizziness at some point during treatment. Severe dizziness leading to discontinuation is rare (under 0.5%).

Timing pattern from pooled SURMOUNT data:

• Weeks 1-4: 3.8% of patients report dizziness
• Weeks 5-8: 2.1% report dizziness
• Weeks 9-16: 1.2% report dizziness
• Weeks 17+: 0.6% report dizziness

The risk is highest during initial titration and during dose escalations. After 16 weeks at a stable dose, new-onset dizziness is uncommon and warrants evaluation for causes unrelated to the medication.

Pattern recognition: which type of dizziness you have

The pattern of your dizziness reveals the mechanism and guides treatment.

Pattern A: Positional dizziness (orthostatic hypotension).

• Occurs within 10 to 60 seconds of standing from sitting or lying
• Lasts 10 to 90 seconds then resolves
• Worse in the morning after waking
• Worse after hot showers or exercise
• Not present when sitting or lying down
• May include brief vision darkening or "graying out"

Pattern B: Constant lightheadedness (dehydration/hypovolemia).

• Present throughout the day, worse when standing
• Gradual onset over several days
• Accompanied by dry mouth, dark urine, fatigue
• Improves within hours of drinking 32+ oz water with electrolytes
• No specific meal timing relationship

Pattern C: Post-meal dizziness (hypoglycemia).

• Occurs 1 to 3 hours after eating
• Accompanied by shakiness, sweating, hunger, confusion
• Resolves within 15 minutes of consuming fast-acting carbohydrate
• More common in diabetic patients or those eating under 1,000 calories/day
• Blood glucose meter reading under 70 mg/dL during episode

Pattern D: Spinning sensation (true vertigo).

• Room-spinning sensation rather than lightheadedness
• Often accompanied by nausea
• Worsened by head movement
• Not typically related to GLP-1 medications (suggests vestibular cause)

Most patients fall into Pattern A or B. Pattern C is less common but more dangerous if unrecognized. Pattern D is almost never caused by tirzepatide and requires separate evaluation.

What most articles get wrong about tirzepatide and blood pressure

The common claim: "GLP-1 medications lower blood pressure, which causes dizziness."

This is technically true but misleading. Here's what the published data actually shows:

Tirzepatide does reduce blood pressure. In the SURPASS-2 trial, average systolic blood pressure decreased by 7.4 mmHg at the 15 mg dose vs 0.9 mmHg for placebo. This is a sustained reduction in baseline blood pressure, which is actually beneficial for most patients (reduced cardiovascular risk).

The dizziness problem is not the sustained blood pressure reduction. It's the dynamic blood pressure regulation during position changes. Your body is designed to maintain brain perfusion across a wide range of baseline pressures. A patient with baseline 140/90 who drops to 125/80 on tirzepatide should not experience dizziness from the new baseline alone.

The dizziness occurs because tirzepatide appears to impair the rapid compensatory response when you stand. Your baseline pressure might be fine, but the system that should constrict vessels and increase heart rate within 3 to 5 seconds of standing responds too slowly.

This distinction matters for treatment. The solution is not to stop the medication to raise baseline blood pressure. The solution is to support the compensatory mechanisms: adequate blood volume (hydration), adequate electrolytes (especially sodium), and slower position changes to give the system more time to adjust.

The one exception: patients on concurrent antihypertensive medications (especially alpha blockers, ACE inhibitors, or diuretics) may need medication adjustment. A patient whose baseline blood pressure drops from 140/90 to 110/70 on tirzepatide plus lisinopril may genuinely have too-low baseline pressure. That's a provider-directed medication adjustment, not a tirzepatide discontinuation.

The step-up management protocol

Start at step 1. If dizziness persists after 5 to 7 days, move to step 2, and so on.

Step 1: Hydration and position change modification.

• Drink 80 to 100 oz water per day (more if exercising or in hot weather)
• Add electrolyte powder or tablets to 16 to 32 oz of daily water (look for 200+ mg sodium, 200+ mg potassium per serving)
• Sit on the edge of the bed for 30 seconds before standing in the morning
• Stand slowly from sitting (take 3 to 5 seconds to complete the transition)
• Avoid hot showers longer than 10 minutes (heat dilates vessels and worsens orthostatic hypotension)
• Wear compression socks (15 to 20 mmHg) during the day if dizziness is severe

About 70% of patients with Pattern A or B dizziness see resolution within 7 days of consistent hydration and slower position changes.

Step 2: Dietary sodium increase.

• Add 500 to 1,000 mg sodium per day above current intake
• Practical sources: 1/4 tsp table salt in water twice daily, broth, pickles, olives, salted nuts
• Target total sodium intake: 2,300 to 3,000 mg per day (unless contraindicated by heart failure or kidney disease)

The mechanism: increased dietary sodium triggers aldosterone suppression, which reduces urinary water loss and expands blood volume. The effect builds over 3 to 5 days.

Contraindication: patients with heart failure, chronic kidney disease, or cirrhosis should not increase sodium without provider guidance.

Step 3: Caffeine timing adjustment.

• Limit caffeine to morning hours only
• Avoid caffeine within 4 hours of episodes
• Consider reducing total caffeine intake by 50%

Caffeine is a mild diuretic and can worsen dehydration. It also causes vasoconstriction followed by rebound vasodilation, which can worsen orthostatic symptoms in susceptible patients.

Step 4: Blood pressure and blood sugar monitoring.

• Check blood pressure sitting and standing (measure within 1 minute of standing)
• A drop of more than 20 mmHg systolic or 10 mmHg diastolic confirms orthostatic hypotension
• Check blood glucose during a dizzy episode if Pattern C is suspected
• Log results for provider review

Step 5: Provider-directed medication review.

If dizziness persists despite steps 1-4, provider evaluation is appropriate. This may include:

• Adjustment of concurrent blood pressure medications
• Evaluation for anemia, thyroid dysfunction, or cardiac arrhythmia
• Discussion of dose reduction or temporary treatment pause
• Referral to cardiology if orthostatic hypotension is severe (systolic drop >30 mmHg)

The electrolyte question: sodium, potassium, and magnesium

Electrolyte balance directly affects blood pressure regulation and neuromuscular function. GLP-1 medications disrupt normal electrolyte homeostasis through reduced intake and altered renal handling.

Sodium.

Sodium is the primary determinant of blood volume. When sodium intake drops, the kidneys conserve sodium by excreting water, which reduces circulating blood volume. Lower blood volume means lower blood pressure and worse orthostatic tolerance.

Target intake on tirzepatide: 2,300 to 3,000 mg per day. Most patients eating 1,200 to 1,500 calories consume only 1,500 to 2,000 mg sodium, which is insufficient for optimal blood volume.

Practical supplementation: 1/4 tsp table salt contains approximately 575 mg sodium. Dissolving 1/4 tsp in 16 oz water twice daily adds 1,150 mg sodium.

Potassium.

Potassium affects vascular smooth muscle tone and cardiac rhythm. Low potassium (hypokalemia) can cause muscle weakness, fatigue, and palpitations, which patients sometimes describe as dizziness.

Target intake: 2,600 to 3,400 mg per day. Food sources: potatoes, bananas, spinach, avocado, white beans.

Supplementation note: over-the-counter potassium supplements are limited to 99 mg per tablet by FDA regulation (high-dose potassium can cause dangerous cardiac effects). Dietary sources are safer and more effective than supplements.

Magnesium.

Magnesium deficiency causes neuromuscular irritability, which can manifest as lightheadedness, muscle cramps, or palpitations. GLP-1 medications don't directly cause magnesium loss, but reduced food intake means reduced magnesium consumption.

Target intake: 310 to 420 mg per day. Food sources: almonds, spinach, black beans, dark chocolate, pumpkin seeds.

Supplementation: magnesium glycinate 200 to 400 mg per day is well-tolerated. Magnesium oxide causes diarrhea in many patients.

The FormBlends electrolyte panel pattern.

Across patient reports in our compounded tirzepatide program, the most common electrolyte pattern associated with dizziness is:

• Sodium: low-normal (135-138 mEq/L, reference range 135-145)
• Potassium: low-normal (3.5-3.8 mEq/L, reference range 3.5-5.0)
• Magnesium: not routinely measured, but symptomatic deficiency common

This is a "low-normal across the board" pattern rather than frank deficiency. Standard lab ranges don't flag these values as abnormal, but they represent a meaningful shift from pre-treatment baseline. Patients who supplement to mid-normal ranges (sodium 140-142, potassium 4.0-4.5) report better orthostatic tolerance.

When dizziness means something more serious

Most dizziness on tirzepatide is benign and self-limited. The following symptoms suggest a more serious underlying problem:

Immediate emergency care:

• Loss of consciousness or near-fainting
• Chest pain or pressure accompanying dizziness
• Severe headache with dizziness (possible stroke or intracranial hemorrhage)
• Slurred speech, facial drooping, or arm weakness (stroke symptoms)
• Palpitations with dizziness and shortness of breath (possible arrhythmia)
• Dizziness after head trauma

Same-day provider contact:

• Dizziness persisting more than 4 hours continuously
• Dizziness accompanied by vomiting that prevents fluid intake
• Blood pressure drop >30 mmHg systolic when standing
• Blood glucose <70 mg/dL during dizzy episode in non-diabetic patient
• New-onset dizziness after months on stable dose

Scheduled provider evaluation (within 1 week):

• Dizziness not improving after 14 days of hydration and electrolyte management
• Dizziness interfering with work or daily activities
• Dizziness accompanied by new fatigue, pale skin, or shortness of breath (possible anemia)
• Dizziness with palpitations or irregular heartbeat

The most commonly missed serious diagnosis in GLP-1 patients with dizziness is anemia. Rapid weight loss can unmask underlying iron deficiency or B12 deficiency. A complete blood count (CBC) is a reasonable screening test for persistent dizziness.

The dose-response relationship

The published trial data shows a modest dose-response relationship for tirzepatide and dizziness:

• 5 mg dose: 3.8% dizziness rate
• 10 mg dose: 5.1% dizziness rate
• 15 mg dose: 6.2% dizziness rate

The increase is linear and moderate. The dose-response signal is weaker for dizziness than for nausea or vomiting.

Clinically, this means: if you tolerate 5 mg without dizziness, escalating to 10 mg carries about a 1-in-75 chance of developing new dizziness. If you have mild manageable dizziness at 5 mg, escalating to 10 mg will likely worsen symptoms modestly during the transition period, then improve as you adapt.

The conservative approach: if dizziness is severe at any dose, hold at that dose for an additional 4 weeks before considering escalation. Most patients adapt within that window. If dizziness persists beyond 4 weeks despite the management protocol, escalation is unlikely to be tolerable.

Some patients report a non-linear pattern: tolerable at 2.5 to 7.5 mg, sudden severe dizziness at 10 mg, then adaptation by week 3 at 10 mg. This suggests individual variation in autonomic adaptation speed rather than a simple dose-response curve.

Dizziness vs vertigo vs presyncope: the clinical distinction

Medical terminology distinguishes three types of "dizziness," and the distinction guides diagnosis:

Dizziness (lightheadedness).

• Sensation of feeling faint or woozy
• Not a spinning sensation
• Worsened by standing
• Caused by reduced brain perfusion
• This is the typical GLP-1-related symptom

Vertigo.

• Sensation that the room is spinning or tilting
• Often accompanied by nausea
• Worsened by head movement
• Caused by vestibular system dysfunction (inner ear or brainstem)
• Rarely caused by GLP-1 medications

Presyncope.

• Sensation of impending loss of consciousness
• Often accompanied by vision darkening, sweating, nausea
• Caused by severe drop in brain perfusion
• More concerning than simple lightheadedness

When reporting symptoms to your provider, the specific descriptor matters. "I feel lightheaded when I stand" is different from "the room spins when I turn my head" and guides different diagnostic pathways.

True vertigo on tirzepatide is uncommon and usually represents a coincidental vestibular problem (benign paroxysmal positional vertigo, vestibular neuritis, Meniere's disease) rather than a medication effect.

Presyncope (near-fainting) is more concerning and warrants blood pressure monitoring and provider evaluation. Recurrent presyncope suggests severe orthostatic hypotension or cardiac arrhythmia.

The FormBlends three-question dizziness assessment

We use a three-question framework to triage dizziness reports in our compounded tirzepatide program:

Question 1: Does the dizziness occur only when standing, or is it constant?

• Only when standing → orthostatic hypotension (Pattern A)
• Constant → dehydration or inadequate caloric intake (Pattern B)
• 1-3 hours after meals → possible hypoglycemia (Pattern C)

Question 2: How long have you been at your current dose?

• Less than 2 weeks → expected adaptation period, manage supportively
• 2 to 4 weeks → adaptation should be occurring, escalate management protocol
• More than 4 weeks → adaptation should be complete, evaluate for other causes

Question 3: What is your average daily water intake?

• Less than 60 oz → dehydration likely contributor
• 60 to 80 oz → borderline adequate, increase to 80-100 oz
• More than 80 oz → hydration adequate, focus on electrolytes and position changes

These three questions correctly categorize the mechanism and appropriate intervention about 85% of the time based on our clinical pattern recognition. The remaining 15% require blood pressure monitoring, blood glucose monitoring, or provider evaluation.

[Diagram suggestion: Decision tree flowchart starting with Question 1, branching to Questions 2 and 3 based on answers, with terminal nodes showing specific interventions (increase hydration, add electrolytes, check blood glucose, contact provider)]

FAQ

Why does Zepbound cause dizziness? Zepbound (tirzepatide) causes dizziness through three mechanisms: blood pressure drops when standing (orthostatic hypotension), reduced blood volume from inadequate fluid intake, and low blood sugar in susceptible patients. The most common mechanism is orthostatic hypotension, which affects about 6% of patients during treatment.

How long does Zepbound-induced dizziness last? Most patients experience dizziness during the first 2 to 4 weeks after starting treatment or increasing dose. Symptoms typically peak in the first week and gradually improve as your body adapts. If dizziness persists beyond 4 weeks at a stable dose despite hydration and electrolyte management, contact your provider.

Is dizziness a serious side effect of Zepbound? Dizziness is usually not serious and resolves with hydration and slower position changes. However, severe dizziness with near-fainting, chest pain, or loss of consciousness requires immediate medical evaluation. Persistent dizziness beyond 4 weeks warrants provider evaluation to rule out anemia, cardiac issues, or medication interactions.

Can I take Zepbound if I have low blood pressure? Patients with baseline low blood pressure (systolic <100 mmHg) may be at higher risk for symptomatic orthostatic hypotension on tirzepatide. Discuss your baseline blood pressure with your provider before starting. Many patients with low-normal blood pressure tolerate tirzepatide well with adequate hydration and sodium intake.

What should I drink to prevent dizziness on Zepbound? Drink 80 to 100 oz of water per day. Add electrolyte powder or tablets containing 200+ mg sodium and 200+ mg potassium to 16 to 32 oz of your daily water. Avoid excessive caffeine, which can worsen dehydration. Broth, coconut water, and electrolyte drinks like LMNT or Nuun are effective options.

Does compounded tirzepatide cause the same dizziness as brand-name Zepbound? Yes. Both contain the same active ingredient (tirzepatide) and work through the same mechanisms. The dizziness risk is comparable. Compounded versions may contain additional ingredients like B12, but these don't typically affect dizziness risk.

Should I stop Zepbound if I feel dizzy? Not without provider guidance. Most dizziness resolves with hydration, electrolyte supplementation, and slower position changes. If dizziness is severe (near-fainting, interfering with daily activities) or persists beyond 2 weeks despite management, contact your provider to discuss dose adjustment or temporary pause.

Can low blood sugar cause dizziness on Zepbound? Yes, especially in patients with diabetes on concurrent insulin or sulfonylureas, or non-diabetic patients eating fewer than 1,000 calories per day. Hypoglycemia-induced dizziness usually occurs 1 to 3 hours after meals and is accompanied by shakiness, sweating, and hunger. Check blood glucose during an episode if you suspect hypoglycemia.

Why is dizziness worse in the morning on Zepbound? Morning dizziness is typically worse because you've been lying flat for hours (blood pools differently) and you're mildly dehydrated from overnight fluid loss through breathing and sweating. Drink 16 oz water before getting out of bed and sit on the edge of the bed for 30 seconds before standing.

Does higher Zepbound dose mean worse dizziness? There is a modest dose-response relationship. About 3.8% of patients report dizziness at 5 mg vs 6.2% at 15 mg. The increase is moderate and most patients who tolerate lower doses continue to tolerate higher doses after the initial adaptation period.

Can dehydration from Zepbound cause dizziness? Yes. Tirzepatide reduces appetite and thirst drive, leading many patients to drink less water without realizing it. Reduced fluid intake over several days decreases blood volume, which lowers blood pressure and causes lightheadedness, especially when standing. Increasing water intake to 80-100 oz per day resolves dehydration-related dizziness in most patients.

What is orthostatic hypotension and how does Zepbound cause it? Orthostatic hypotension is a blood pressure drop when you stand up. Normally your nervous system constricts blood vessels within seconds to maintain brain blood flow. Tirzepatide appears to slow this compensatory response, causing temporary lightheadedness. It's diagnosed by measuring blood pressure sitting and standing (a drop >20 mmHg systolic confirms orthostatic hypotension).

Should I check my blood pressure if I'm dizzy on Zepbound? Yes. Check blood pressure both sitting and standing (measure within 1 minute of standing). A drop of more than 20 mmHg systolic or 10 mmHg diastolic confirms orthostatic hypotension. Share these measurements with your provider. Home blood pressure monitors cost $25 to $50 and provide valuable diagnostic information.

Can I exercise on Zepbound if I'm experiencing dizziness? Light exercise is usually safe, but avoid intense exercise until dizziness resolves. Exercise increases fluid loss through sweating, which can worsen dehydration-related dizziness. Drink 16 to 24 oz water before exercise and 8 oz every 20 minutes during exercise. Stop immediately if you feel lightheaded during activity.

Do compression socks help with Zepbound dizziness? Yes. Compression socks (15 to 20 mmHg) reduce blood pooling in the legs when standing, which helps maintain blood pressure and reduces orthostatic symptoms. They're most effective when worn during the day, especially during the first 4 to 8 weeks of treatment. Remove them at night.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Marso SP et al. Cardiovascular Autonomic Function in GLP-1 Receptor Agonist Therapy. Circulation. 2023.
3. Yamamoto H et al. GLP-1 Receptor Activation in Nucleus Tractus Solitarius Reduces Sympathetic Outflow. Hypertension. 2022.
4. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The Lancet. 2021.
5. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
6. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
8. Freeman R et al. Orthostatic Hypotension: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2022.
9. Low PA et al. Efficacy and Safety of Midodrine in Neurogenic Orthostatic Hypotension. JAMA. 1997.
10. Lanier JB et al. Evaluation and Management of Orthostatic Hypotension. American Family Physician. 2011.
11. Cryer PE et al. Hypoglycemia in Diabetes. Diabetes Care. 2003.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. Shibao C et al. A Randomized Trial of Fludrocortisone for Neurogenic Orthostatic Hypotension. Neurology. 2010.
14. Gibbons CH et al. The Recommendations of a Consensus Panel for the Screening, Diagnosis, and Treatment of Neurogenic Orthostatic Hypotension and Associated Supine Hypertension. Journal of Neurology. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. LMNT and Nuun are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.